1086381-30-7 Usage
Description
4-Bromo-2-tert-butylpyridine is a chemical compound belonging to the pyridine class, characterized by a six-membered ring with two non-adjacent nitrogen atoms. The presence of a bromine atom and a tert-butyl group significantly modifies its chemical properties, making it highly relevant for various synthesis processes in organic and medicinal chemistry. Its reactivity, polarity, and basicity can be strategically utilized in different chemical transformations. However, it is crucial to handle this compound with care due to its potentially harmful effects.
Uses
Used in Organic Chemistry:
4-Bromo-2-tert-butylpyridine is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure and reactivity make it a valuable building block in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 4-bromo-2-tert-butylpyridine is used as a key component in the development of new drugs. Its chemical properties allow it to be incorporated into drug molecules, potentially enhancing their therapeutic effects and selectivity.
Used in Chemical Transformations:
4-Bromo-2-tert-butylpyridine is utilized as a reactant in various chemical transformations, such as cross-coupling reactions, substitution reactions, and condensation reactions. Its reactivity and polarity contribute to the formation of desired products with high yields and selectivity.
Used in Research and Development:
In academic and industrial research settings, 4-bromo-2-tert-butylpyridine serves as a valuable compound for exploring new reaction mechanisms, developing novel synthetic methods, and discovering potential applications in various fields, including materials science, agrochemistry, and environmental chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1086381-30-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,6,3,8 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1086381-30:
(9*1)+(8*0)+(7*8)+(6*6)+(5*3)+(4*8)+(3*1)+(2*3)+(1*0)=157
157 % 10 = 7
So 1086381-30-7 is a valid CAS Registry Number.
1086381-30-7Relevant articles and documents
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Furet, Pascal,Guagnano, Vito,Fairhurst, Robin A.,Imbach-Weese, Patricia,Bruce, Ian,Knapp, Mark,Fritsch, Christine,Blasco, Francesca,Blanz, Joachim,Aichholz, Reiner,Hamon, Jacques,Fabbro, Doriano,Caravatti, Giorgio
, p. 3741 - 3748 (2013)
Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719.
A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER
-
, (2017/03/28)
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha- isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER
-
, (2017/03/21)
The present disclosure pertains to a pharmaceutical combination comprising (a) alpha- isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
